NEUP

Neuphoria Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$20.81M
P/E Ratio
EPS
$-8.39
Beta
52W High
$21.40
52W Low
$3.19
50-Day MA
$4.32
200-Day MA
$5.02
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company dedicated to transforming the treatment landscape for mental health disorders through the use of psychedelic compounds and state-of-the-art drug delivery systems. With a robust pipeline of promising preclinical candidates, Neuphoria is strategically positioned to address significant unmet needs in mental healthcare, aligning with the growing acceptance and demand for alternative therapeutic modalities. As a leader in the emerging psychedelic therapy market, the company presents a compelling investment opportunity for institutional investors interested in pioneering advancements that may redefine mental health treatment approaches.

Official WebsiteUSAFY End: June

Fundamentals

Revenue (TTM)-13,267
Gross Profit (TTM)-13,267
EBITDA$-14.00M
Operating Margin110513.00%
Return on Equity-62.90%
Return on Assets-28.00%
Revenue/Share (TTM)$-0.00
Book Value$5.47
Price-to-Book0.70
Price-to-Sales (TTM)1.70
EV/Revenue0.224
EV/EBITDA-0.06
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$5.40M
Float$4.19M
% Insiders7.70%
% Institutions55.03%

Historical Volatility

HV 10-Day
102.56%
HV 20-Day
106.74%
HV 30-Day
90.22%
HV 60-Day
74.41%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($7.00 target)
1
Hold

Latest News

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

GlobeNewsWire7/28/2026Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

NEW YORK, July 24, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Neuphoria Therapeutics, Inc. (NASDAQ: NEUP ) related to its merger with Scancell Holdings plc.

PRNewsWire7/24/2026Neutral
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria”) today announce an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the         Transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol “SCLT”.

GlobeNewsWire7/23/2026Neutral
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc (“Scancell”).

GlobeNewsWire6/26/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NEUP and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026